Inspire Investing LLC Has $353,000 Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

Inspire Investing LLC grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 15.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,643 shares of the biopharmaceutical company’s stock after purchasing an additional 2,563 shares during the period. Inspire Investing LLC’s holdings in Xencor were worth $353,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Diversified Trust Co raised its stake in Xencor by 4.5% during the 1st quarter. Diversified Trust Co now owns 13,059 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 563 shares during the period. Texas Permanent School Fund Corp lifted its holdings in shares of Xencor by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 690 shares in the last quarter. Linden Thomas Advisory Services LLC grew its position in Xencor by 1.6% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock valued at $826,000 after purchasing an additional 699 shares during the period. Baillie Gifford & Co. increased its stake in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock valued at $445,000 after purchasing an additional 744 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 900 shares during the last quarter.

Xencor Trading Down 0.6 %

NASDAQ XNCR opened at $21.07 on Monday. The business’s fifty day moving average is $18.59 and its 200-day moving average is $20.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -9.62 and a beta of 0.66. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84.

Xencor (NASDAQ:XNCR) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The company had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. The firm’s revenue was down 62.7% compared to the same quarter last year. Equities research analysts predict that Xencor, Inc. will post -4.17 EPS for the current year.

Insider Activity at Xencor

In other Xencor news, VP John R. Desjarlais sold 36,329 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the sale, the vice president now directly owns 192,319 shares of the company’s stock, valued at $3,523,284.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.23% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Xencor in a research report on Monday, September 9th. Raymond James lowered their price objective on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Friday, June 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 target price on shares of Xencor in a research report on Tuesday, August 6th. BMO Capital Markets reiterated an “outperform” rating and set a $32.00 price target on shares of Xencor in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. dropped their price objective on Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.44.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.